Rubius Therapeutics CEO Pablo Cagnoni's 2020 pay jumps 100% to $3.4M
Rubius Therapeutics reports 2020 executive compensation
By ExecPay News
Published: March 30, 2022
Rubius Therapeutics reported fiscal year 2020 executive compensation information on March 30, 2022.
In 2020, four executives at Rubius Therapeutics received on average a compensation package of $2.2M, a 40% increase compared to previous year.
Average pay of disclosed executives at Rubius Therapeutics
Pablo J. Cagnoni, Chief Executive Officer, received $3.4M in total, which increased by 100% compared to 2019. 71% of Cagnoni's compensation, or $2.4M, was in option awards. Cagnoni also received $410K in bonus, $579K in salary, as well as $17K in other compensation.
Christina Coughlin, Chief Medical Officer, received a compensation package of $2.5M. 72% of the compensation package, or $1.8M, was in option awards.
Laurence Turka, Chief Scientific Officer, earned $2.4M in 2020.
Maiken Keson-Brookes, Chief Legal Officer, received $611K in 2020, which decreases by 59% compared to 2019.
Related executives
You may also like
Source: SEC filing on March 30, 2022.